Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

Abstract

5536 Background: The primary endpoint for clinical trials in PRR/PPS ≥ 3 ROC is progression free survival (PFS) and symptom benefit is not typically measured or reported. The primary aim of GCIG SB...